Myelodysplastic Syndromes — Higher-Risk (IPSS-R high / very high; includes MDS-EB) · Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-VEN-AZA-AML |
| ID | IND-MDS-HR-1L-VEN-AZA |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MDS-HR |
| Sources | SRC-NCCN-AML-2025 SRC-VIALE-A-DINARDO-2020 |
Notes
Aggressive track for MDS-HR. NCCN 2A given off-label status pending phase-3. STUB — requires clinical co-lead signoff. Open clinical question for clinical reviewer: should this indication be removed pending phase-3, or kept as scaffolded option?
Used By
Algorithms
ALGO-MDS-HR-1L- ALGO-MDS-HR-1LALGO-MDS-HR-2L- ALGO-MDS-HR-2L